Intramuscular Generic Injection (QLG2072) versus Haloperidol in Chinese Patients with Acute Agitation: A Phase 3 Multicenter, Randomized, Double-Blind, Active-Controlled Trial.
Fang Dong, Zhonggang Wang, Chao Li, Xuan Li, Daomin Zhu, Jie Li, Zhoubing Wang, Jian Gong, Jianchu Zhou, Huanzhong Liu, Yunshu Zhang, Xuehua Zhang, Xiuzhe Chen, Mei Yu, Xi Tan, Mincai Qian, Yu Luo, Wan-Jun Guo, Shiping Xie, Jinsong Huang, Jingyuan Zhao, Jianguo Wan, Yihui Shan, Nannan Li, Jie Wang, Yunfei Ju, Juan Wang, Qingtao Bian, Gang Wang
Drug Des Devel Ther 20 561494
摘要
摘要
INTRODUCTION: This multicenter, randomized, double-blind, phase 3 trial aimed to assess the efficacy and safety of generic olanzapine injection (QLG2072) in managing acute agitation associated with schizophrenia/bipolar I disorder in Chinese patients. METHODS: Patients with acute agitation associated with schizophrenia/bipolar I disorder were randomly (1:1) assigned to receive 1-3 intramuscular (IM) injections within a 24-hour treatment period, with either QLG2072 (10 mg per injection) or haloperidol (7.5 mg per injection). The primary endpoint was the change in Positive and Negative Syndrome Scale-Excited Component (PANSS-EC) score from baseline to 2 hours post-injection, assessed against a pre-specified non-inferiority margin of 2.0 for QLG2072 versus haloperidol. RESULTS: A total of 318 participants were randomized; 159 and 158 were included in the olanzapine and haloperidol FAS groups, respectively. At 2 h post-injection, the adjusted mean reductions in PANSS-EC scores were -9.37 (95% confidence interval [CI]: -10.02 to -8.72) for QLG2072 versus -9.40 (95% CI: -10.04 to -8.75) for IM haloperidol with a between-group difference of 0.03 (95% CI: -0.88 to 0.93), establishing non-inferiority of QLG2072 to IM haloperidol, as the upper limit of the 95% CI fell below the predefined margin. Consistent with the primary endpoint, comparable efficacy was observed across multiple secondary efficacy measures, including response rate and the Clinical Global Impression-Improvement scores. The overall incidence of treatment-emergent adverse events was comparable between the treatment groups. However, QLG2072 was associated with a numerically lower incidence of extrapyramidal symptoms compared to haloperidol (10.1% vs 27.2%). DISCUSSION: QLG2072 demonstrated non-inferiority to haloperidol in acute agitation management, with comparable efficacy and favorable neurological tolerability. These findings support its clinical application in Chinese psychiatric populations. TRIAL REGISTRATION: ClinicalTrials.gov: NCT05803642.
KM 提取结果
0 个 Figure · 0 个 KM 面板
其他 Figure(3,默认折叠)
这些图片未产生 KM 曲线结果,不在主页面重复展示。